- Home
- PMEC vs SNSE Comparison
PMEC vs SNSE Comparison
Compare PMEC & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- SNSE
- Stock Information
- Founded
- PMEC 1984
- SNSE 2005
- Country
- PMEC Singapore
- SNSE United States
- Employees
- PMEC N/A
- SNSE N/A
- Industry
- PMEC
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- SNSE Health Care
- Exchange
- PMEC Nasdaq
- SNSE Nasdaq
- Market Cap
- PMEC 56.9M
- SNSE 10.5M
- IPO Year
- PMEC 2023
- SNSE 2021
- Fundamental
- Price
- PMEC $1.81
- SNSE $9.01
- Analyst Decision
- PMEC
- SNSE Strong Buy
- Analyst Count
- PMEC 0
- SNSE 4
- Target Price
- PMEC N/A
- SNSE $72.50
- AVG Volume (30 Days)
- PMEC 239.8K
- SNSE 6.5K
- Earning Date
- PMEC 01-01-0001
- SNSE 11-13-2025
- Dividend Yield
- PMEC N/A
- SNSE N/A
- EPS Growth
- PMEC N/A
- SNSE N/A
- EPS
- PMEC N/A
- SNSE N/A
- Revenue
- PMEC $74,349,000.00
- SNSE N/A
- Revenue This Year
- PMEC N/A
- SNSE N/A
- Revenue Next Year
- PMEC N/A
- SNSE N/A
- P/E Ratio
- PMEC N/A
- SNSE N/A
- Revenue Growth
- PMEC 2.52
- SNSE N/A
- 52 Week Low
- PMEC $0.54
- SNSE $5.00
- 52 Week High
- PMEC $1.89
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- PMEC 57.11
- SNSE 57.00
- Support Level
- PMEC $1.76
- SNSE $8.41
- Resistance Level
- PMEC $1.88
- SNSE $9.49
- Average True Range (ATR)
- PMEC 0.10
- SNSE 0.57
- MACD
- PMEC 0.00
- SNSE 0.07
- Stochastic Oscillator
- PMEC 79.49
- SNSE 71.11
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).